CSL (AU:CSL)
ASX:CSL
Want to see AU:CSL full AI Analyst Report?
CSL Stock Chart & Stats
AU$137.13
-AU$0.78(-0.27%)
At close: 4:00 PM EST
AU$137.13
-AU$0.78(-0.27%)
Day’s Range― - ―
52-Week RangeAU$93.64 - AU$275.79
Previous CloseN/A
Volume375.76K
Average Volume (3M)974.43K
Market Cap
AU$47.54B
Enterprise ValueAU$44.31B
Total Cash (Recent Filing)AU$1.15B
Total Debt (Recent Filing)AU$12.58B
Price to Earnings (P/E)22.9
Beta0.64
Next Earnings
Aug 18, 2026EPS Estimate
3.13Next Dividend Ex-DateN/A
Dividend Yield2.58%
Share Statistics
EPS (TTM)2.98
Shares Outstanding478,912,000
10 Day Avg. Volume1,091,561
30 Day Avg. Volume974,433
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)3.94
Price to Sales (P/S)4.94
P/FCF Ratio29.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$146.86Price Target Upside7.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)6.33
Revenue Forecast (FY)AU$15.40B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & Capital ReturnsSustained operating cash flow ($1.3bn H1) and material buybacks/dividend reflect durable cash conversion. FinancialAnalysis.CashFlow notes 25.2% FCF growth and OCF/net income of 1.19, supporting reinvestment, transformation costs and shareholder returns without straining liquidity.
Balanced Balance Sheet And Strong MarginsModerate leverage (D/E ~0.59) and robust ROE signal a balanced capital structure. Coupled with high gross (51.5%) and net (19.5%) margins from the income summary, this provides resilience to fund R&D, absorb shocks, and sustain profitability over the medium term.
Diversified Franchise And Pipeline MomentumGrowth from new launches (HEMGENIX, ANDEMBRY) plus Vifor double-digit performance and pipeline moves (VarmX entering Phase III, partnerships) diversify revenue streams. This reduces reliance on single products and supports medium-term growth if launches and trials progress as planned.
Bears Say
Large Non-cash ImpairmentsMaterial impairments (~$1.1bn FY26, $1.05bn in H1) indicate prior investments or assets that underperformed. Even if non-cash, they compress reported earnings, raise questions on past R&D/licensing choices, and increase scrutiny and execution risk for the transformation program over the coming months.
Immunoglobulin Reimbursement HeadwindsPolicy-driven reimbursement changes (Medicare Part D) and expired contracts hit core Ig products. Since immunoglobulins are a material revenue base, persistent regulatory or tender pressure can structurally reduce volumes/pricing, making medium-term recovery dependent on new contracts or policy shifts.
China Albumin Policy ExposureGovernment enforcement and cost controls in China have materially depressed albumin volumes. Because China is a significant market, policy-driven demand and pricing constraints create structural uncertainty for albumin revenue and margins until policy or procurement dynamics improve.
CSL News
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$93.64 and its highest was AU$275.79 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is AU$47.54B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Aug 18, 2026 which is in 80 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Feb 10, 2026. The company reported AU$5.66 earnings per share for the quarter, missing the consensus estimate of AU$5.815 by -AU$0.155.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$2.451 which represents an annual dividend yield of 2.58%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 3.13.
How many shares outstanding does CSL have?
CSL has 478,912,000 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$5.66 in its last earnings report, missing expectations of AU$5.815. Following the earnings report the stock price went down -4.638%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$146.86 (7.10% Upside)
AU$146.86 (7.10% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$358.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSL Company Deck
CSL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: operational strengths (strong cash generation, share buyback expansion, cost-savings progress, solid Vifor performance, successful new product launches and Seqirus commercial gains) are offset by meaningful near-term pressures (H1 revenue decline, major non-cash impairments and one-off restructuring costs, policy-driven weakness in albumin and Ig headwinds, iron generics and KCENTRA competitive pricing). Management emphasizes these impairments are largely non‑cash, that the transformation is delivering tangible savings, and they have maintained full-year guidance while laying out remediation steps for weaker areas. The tone is cautiously constructive but with material near-term risks that require execution in H2 to validate the outlook.View all AU:CSL earnings summariesCSL Stock 12 Month Forecast
Average Price Target
AU$146.86
▲(7.10% Upside)
Technical Analysis
Opthea
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---